• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Naltrexone helps HIV positive individuals reduce heavy alcohol use

Bioengineer by Bioengineer
August 7, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New Haven, Conn. – Extended-release naltrexone — an injection that decreases heavy drinking in the general population when taken in conjunction with counseling — appears to help HIV-positive individuals reduce their number of heavy drinking days too, say Yale researchers.

This study was published online on Aug. 2 in AIDS and Behavior.

"While we know that patients with heavy alcohol use are less likely to take their medications for HIV, there is a paucity of interventions that target alcohol use to improve how patients take their medications," said Jennifer Edelman, M.D., first author and associate professor at the Yale School of Medicine. "Extended-release naltrexone is a medication that is safe and effective for patients living with HIV that can be delivered in HIV treatment settings that could potentially help this problem."

Conducted between April 2011 and February 2015, the trial involved 51 HIV positive individuals who exhibited heavy drinking and suboptimal (less than 95%) antiretroviral adherence. All the participants in the study received counseling. Researchers found that the extended-release naltrexone led to clinically and statistically significant decreases in the number of heavy drinking days for the participants.

However, the researchers saw no appreciable effect of the extended-release naltrexone, versus a placebo, on the adherence of HIV-positive individuals to their antiretroviral therapy regimens.

"We hope that these results will stimulate further research focused on enhancing the coupling of alcohol interventions with antiretroviral medication adherence interventions to improve both alcohol use and HIV related outcomes," said Lynn Fiellin, M.D., senior author, director of the Yale Center for Health and Learning Games, and associate professor at the Yale School of Medicine.

###

Other authors on this study include Brent A. Moore, Stephen R. Holt, Nathan Hansen, Tassos C. Kyriakides, Michael Virata, Sheldon Brown, Amy C. Justice, Kendall J. Bryant, and David A. Fiellin.

This study was funded by the U.S. National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism.

Aids and Behavior DOI: 10.1007/s10461-018-2241-z

Media Contact

Kendall Teare
[email protected]
203-836-4226
@yale

http://www.yale.edu

http://dx.doi.org/10.1007/s10461-018-2241-z

Share12Tweet8Share2ShareShareShare2

Related Posts

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

July 6, 2026

Kidney transplant outcomes in older adults studied by German researchers

July 6, 2026

Salmonella protein SopB curbs early inflammation to slow disease progression

July 6, 2026

Multi-metal cooperation drives lung cancer chemoresistance, reversed by MiADMSA

July 6, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Flame retardant BDE-209 targets molecularly linked to ulcerative colitis

Ultra-high frequency particle impacts mimic rockbursts to shatter hard rock

Kidney transplant outcomes in older adults studied by German researchers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.